

Data sheet – cycle 1

Reviewing type 2 diabetes management in patients at high risk of cardiovascular and renal complications

Patient with type 2 diabetes	A	B	C	D	E	F	G	H
	HbA _{1c} > 53 mmol/mol	CVD/risk > 15%	DKD	HF	Māori or Pacific ethnicity	Eligible for funded treatment (tick in column A + at least one tick in columns B – D)	If Yes in column F, prescribed empagliflozin or dulaglutide	If No in column G, flag for review
	✓/✗	✓/✗	✓/✗	✓/✗	✓/✗	Yes/No	Yes/No	
1								
2								
3								
4								
5								
6								
7								
8								
9								
10								
11								
12								
13								
14								
15								
16								
17								
18								
19								
20								
21								
22								
23								
24								
25								
26								
27								
28								
29								
30								

AUDIT RESULT: Total 'YES' in column G divided by total 'YES' in column F :

Please retain this sheet for your records to provide evidence of participation in this audit.

Data sheet – cycle 2 Reviewing type 2 diabetes management in patients at high risk of cardiovascular and renal complications

Patient with type 2 diabetes	A	B	C	D	E	F	G	H
	HbA _{1c} > 53 mmol/mol	CVD/risk > 15%	DKD	HF	Māori or Pacific ethnicity	Eligible for funded treatment (tick in column A + at least one tick in columns B – D)	If Yes in column F, prescribed empagliflozin or dulaglutide	If No in column G, flag for review
	✓/✗	✓/✗	✓/✗	✓/✗	✓/✗	Yes/No	Yes/No	
1								
2								
3								
4								
5								
6								
7								
8								
9								
10								
11								
12								
13								
14								
15								
16								
17								
18								
19								
20								
21								
22								
23								
24								
25								
26								
27								
28								
29								
30								

AUDIT RESULT: Total 'YES' in column G divided by total 'YES' in column F :

Please retain this sheet for your records to provide evidence of participation in this audit.



SUMMARY SHEET

Audit of medical practice (CQI activity)

Topic:

Reviewing type 2 diabetes management in patients at high risk of cardiovascular and renal complications

Date:

Activity designed by (name of organisation, if relevant):

Bpac^{nz}

Doctor's name:

Results discussed with peer group or colleagues?

Yes

No

Date:

FIRST CYCLE

DATA: Date of data collection:

CHECK: Describe any areas targeted for improvement as a result of analysing the data collected. (If the findings have any implications for health equity, please include this.)

ACTION: Describe how these improvements will be implemented.

MONITOR: Describe how well the process is working. When will you undertake a second cycle?

SECOND CYCLE

DATA: Date of data collection:

CHECK: Describe any areas targeted for improvement as a result of analysing the data collected. (If the findings have any implications for health equity, please include this.)

ACTION: Describe how these improvements will be implemented.

MONITOR: Describe how well the process is working.

COMMENTS: